Background: Clarithromycin displays immunomodulatory and antineoplastic properties. As single agent, this macrolide is associated with tumor responses in anecdotal cases of relapsed/refractory extranodal marginal zone lymphoma (rrEMZL), with a putative dose-dependent effect. Tolerability and activity of high-dose clarithromycin (HD-K) in patients with rrEMZL were addressed in a phase II trial (clinicaltrials.gov NCT01516606).
introduction
Marginal zone lymphoma arising in extranodal organs (extranodal marginal zone lymphoma, EMZL) is an indolent malignancy characterized by high-response rates to conventional therapies, long-lasting persistence of residual disease, mild-related symptoms, frequent relapses and low cause-specific mortality [1] . Therapeutic goal in many EMZL patients is to control tumor progression and related symptoms with less aggressive strategies, preventing acute and chronic toxicity. Accordingly, a few welltolerated, easy to administrate, chemotherapy-free approaches such as antimicrobial agents, immunomodulators and targeted therapies have been investigated. The use of antibiotics plays a central role in the treatment of EMZL as this disorder is often associated with chronic bacterial infections [2] . Bacterial eradication with antibiotics leads often to antigenic stimulus removal and eventual lymphoma regression [2] . In addition, some antibiotics display a direct proapoptotic effect on tumor cells. Although the magnitude of their antitumor effect seems to be lower than that of standard chemotherapeutic agents, some antibiotics exhibit multiple antiproliferative mechanisms that deserve to be better explored. Macrolides have been proposed as potential antineoplastic and immunomodulatory agents due to their capability to enhance the antitumor activity of macrophages, NK cells and cytotoxic T cells [3] , to reduce neutrophil production of IL-8 [4] , and to inhibit tumor necrosis factor-α and vascular endothelial growth factor (VEGF) activity [3] . The macrolide clarithromycin is a substrate of P-glycoprotein [5] , induces apoptotic changes in tumor cells [6] and increases intracellular concentrations of anticancer drugs [7] . This antibiotic, alone or combined with anticancer drugs, has shown encouraging antitumor activity in murine models of lung cancer [6] and melanoma [8] . More importantly, the combination of clarithromycin with other immunomodulators has been associated with promising results in patients with multiple myeloma or Waldenström's macroglobulinemia [9, 10] . All these in vitro, preclinical and clinical data have generated great interest in the antineoplastic activity of macrolides, leading investigators to address them in prospective clinical trials.
Since its indolent behavior, EMZL is a suitable candidate to test the antineoplastic effects of antibiotics. As single-agent, conventional-dose clarithromycin has been associated with an overall response rate (ORR) of 38% and a 3-year progressionfree survival (PFS) of 58% in patients with relapsed/refractory EMZL [11] , and a dose-dependent antineoplastic effect has been hypothesized. Accordingly, a new schedule of high-dose clarithromycin (HD-K) was designed and investigated in patients with relapsed/refractory EMZL enrolled in a phase II trial. Herein, we report the final results of this trial, which suggest that HD-K is active against EMZL, exerting an antiproliferative effect that seems to be independent of the eradication of a known chronic infection.
patients and methods

study population
From February 2012 to October 2013, adult patients with relapsed or refractory EMZL diagnosed at the San Raffaele Scientific Institute of Milano, Italy, and at the University of Vienna, Austria, were registered in this phase II trial (clinicaltrials.gov NCT01516606). Selection criteria were: (i) histological diagnosis of EMZL of MALT-type; (ii) disease relapsed from or refractory to chemotherapy, immunotherapy, antibiotic therapy (for lymphomas arising in the stomach or the ocular adnexae) or local therapies (surgery, radiotherapy); (iii) age ≥18 years; (iv) Eastern Cooperative Oncology Group performance status ≤3; (v) at least one measurable/parametrable lesion; (vi) absence of HIV infection. Patients with nodal and splenic MZL were excluded. Baseline assessment included hemogram and biochemical profile, HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV) serology, total body computed tomography (CT) scan, gastroscopy and bone marrow biopsy; gadolinium-enhanced magnetic resonance imaging and ophthalmological examination were carried out in patients with ocular adnexal MZL. All patients were tested for gastric Helicobacter pylori infection with at least two tests among histology, breath test, serology and/or cagA in feces. Chlamydophila psittaci infection was assessed by PCR [12] on tissue and peripheral blood in patients with ocular adnexal MALT lymphoma. Written informed consent was obtained from each enrolled patient. This trial conformed to the tenets of the Declaration of Helsinki, was approved by the Institutional Review Boards of participating institutes and was conducted in accordance with the Harmonization GCP guidelines.
treatment and response assessment
Patients were treated with four courses of oral clarithromycin 2 g/day, once daily, days 1-14, every 21 days. Empty stomach assumption with abundant water was indicated. Tolerability and response were assessed by physical examination, routine laboratory tests, and electrocardiogram every 2 months during clarithromycin treatment. Response (supplementary Table, available at Annals of Oncology online) was based on local investigator assessment and defined according to the NCI standardized response criteria for nonHodgkin's lymphoma [13] and to the GELA criteria for gastric lymphoma [14] . Procedures for response assessment were indicated according to the site of disease (supplementary Table, available at Annals of Oncology online). Best response (maximum response) from the start of the treatment until disease progression was considered. The duration of response was measured from the date of maximum response to the date of objective progression or last date of follow-up. During follow-up, patients were assessed by physical examination, routine laboratory tests and additional imaging and/or endoscopy according to the involved organ every 6 months for 5 years and every 12 months afterwards.
statistical considerations
ORR (complete and partial responses) after HD-K was the primary end point of this trial. The Simon minimax two-stage design was used. The maximum ORR considered of low interest was 40% (P 0 ) [11] and the minimum ORR considered of interest was 70% (P 1 ). The target enrollment (α = 0.05; β = 0.20; two-sided) was estimated to be 21 patients, among whom at least 11 responses were necessary to declare the experimental treatment active against relapsed/refractory EMZL. Feasibility, duration of response, PFS and overall survival (OS) were secondary end points. PFS was calculated from the date of the start of clarithromycin treatment to relapse, progression or death or to the last date of follow-up. OS was calculated from the date of the start of clarithromycin treatment to death or to the last date of follow-up. Survival curves were generated using the Kaplan-Meier method. All analyses were carried out using the Statistica 10.0 statistical package for Windows (Statsoft, Inc., 2011, Tulsa, OK).
results
patient characteristics
Twenty-three patients were enrolled (Table 1) . HD-K was the salvage therapy at first relapse in 12 patients, and the third-fifth line in the others. Seventeen patients had achieved a response to the previous line of treatment, where six patients had refractory disease. Median time to progression from the previous treatment line was 14 months (range 4-108). At trial registration, 17 patients had local (unifocal) disease, and 6 had multiorgan disease. Ocular adnexae (n = 13), stomach (n = 4) and lung (n = 3) were the most commonly involved organs. Five patients had HBV and/or HCV infections; they had no signs of cirrhosis nor abnormal levels of hepatic enzymes. Chronic infections caused by Helicobacter pylori (n = 1) and Chlamydophila psittaci (n = 6) had successfully been eradicated with specific antibiotics as part of first-line treatment, with a median time from bacterial eradication to clarithromycin treatment of 24 (19-90) months; these infections were not detected in registered patients at the time of trial entry, which excludes bona fide that clarithromycin antitumor activity could be due to antimicrobial effect.
feasibility and tolerability
Eighteen patients underwent treatment as scheduled; HD-K was interrupted in five patients due to nausea (n = 2) or progressive disease (n = 3); 79 (86%) of 92 planned courses were delivered. Tolerability was excellent; nausea was the commonest sideeffect, but it was manageable and did not require dose reduction, 
activity ( primary end point)
Six patients achieved a complete remission (Figure 1 ) and six a partial response [ORR = 52%; 95% confidence interval (CI) 32% to 72%]; five patients had stable disease (9, 11, 24+, 24+, 29+ months), six patients experienced progressive disease (within 6 months from trial registration). The best response was achieved immediately after the conclusion of HD-K treatment; there were no cases of late response. Age, previous treatments and number of involved organs did not influence response ( Table 2 ). Four of the seven patients previously treated with rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) achieved an objective response after HD-K (10, 18, 21+ and 24+ months). The five patients with HBV/HCV infections completed the planned treatment without relevant side-effects; three of them achieved an objective response lasting 20+, 21+ and 24+ months.
efficacy After a median follow-up of 24 (16-33) months, only two patients with responsive disease experienced relapse and two patients with stable disease experienced progression, with a 2-year PFS of 56 ± 10% (Figure 2 ). Importantly, median PFS after HD-K (not reached) was longer than those recorded with the immediately previous treatment line (14 months; range 4-108); in particular, PFS after HD-K was longer than those achieved with previous treatment in 8 of the 12 patients treated with a single previous line and in 6 of the 11 patients treated with multiple lines. Age, number of previous therapeutic lines and number of involved organs did not influence PFS, whereas PFS was significantly shorter in patients previously treated with rituximab and in patients with lymphoma refractory to previous treatment (Table 2) . No cases of high-grade transformation occurred. Failures involved the primary sites of disease in all cases but one (retroperitoneal lymph nodes). Salvage treatment consisted of rituximab-bendamustine in five patients, ofatumumab in two, rituximab-lenalidomide in one, chlorambucil in one and radiotherapy in one. Response to salvage therapy was complete in four patients and partial in five. All patients are alive, with a median OS of 24+ months (range: 16-33 months).
discussion
This phase II trial demonstrates that HD-K is a safe and active treatment in patients with relapsed/refractory EMZL. HD-K appears more active than conventional-dose clarithromycin, and its activity is emphasized by the fact that median PFS was not reached at a median follow-up of 24 months, whereas the median PFS from prior therapy was only 14 months. Responses were observed in every primarily involved organ, but this should be taken into account with caution since the small size of some subgroups. As major limitation, the involvement of a clarithromycin-sensitive infectious agent in triggering and maintaining the lymphoma growth was not definitively excluded in this trial. Seven enrolled patients had a history of H. pylori or C. psittaci infections; they were treated with eradicating antibiotics as front-line therapy 2 years before trial enrollment (median), achieving successful microbial eradication without evident lymphoma regression. At the time of trial registration, these infections were not detected in the stomach, diagnostic samples, conjunctival swaps and peripheral blood mononuclear cells, which suggests that responses obtained with HD-K were more probably due to an antitumor or immunomodulatory effect of clarithromycin and not to a simple antibacterial activity. This is in line with anecdotal reported cases of lymphoma regression after macrolides administration in patients with H. pylori-negative MALT lymphoma of the gastrointestinal tract [14] [15] [16] .
The choice of the dose of clarithromycin used in this trial is based on safety and pharmacokinetic data. Maximum tolerated dose of clarithromycin is 3 g twice a day. A dose of 2 g twice a day for up to 24 weeks results in a half-life >18 h, and has been safe in health volunteers and HIV-positive subjects. Thus, a dose 2 g/day was chosen as a good balance between bioavailability and safety. In fact, this dose of clarithromycin was well tolerated, with manageable grade-1 nausea as the most common side-effect and, although median follow-up of this trial is still short, it is plausible to think that HD-K will not result in late effects and sequels. These are important issues considering that patients with relapsing EMZL frequently has mild symptoms and a good quality of life; in fact, these patients often refuse conventional chemotherapy or radiotherapy since it is felt as a sort of overtreatment. In our previous trial, addressing activity of conventional-dose clarithromycin in patients with relapsed or refractory EMZL, ORR was 38%, and responses were exclusively recorded in ocular adnexal lymphomas [11] , which is in line with recent case reports [17, 18] . In the current trial, including a larger series, but with similar characteristics to the previous one, HD-K was associated with an ORR of 52%, and responses were recorded in every primarily involved organ, even in patients with multifocal disease as well as in patients who received several treatment lines. With all the limitations of a comparison between single-arm phase II trials, these figures seem to suggest that clarithromycin is more active when used at high doses, which may be explained by an increased drug bioavailability in tumor tissues, and is in line with in vitro and in vivo studies suggesting a dose-dependent activity [19] .
Safety and efficacy of HD-K should be put in context analyzing reported phase II trials addressing other single drugs in patients with relapsed/refractory EMZL, which is rituximab, bortezomib, everolimus, thalidomide and lenalidomide. Noteworthy, these studies have often included both patients with newly diagnosed and relapsed disease, and, sometimes, all the three forms of MZL, rendering the difficult comparison. Rituximab has been associated with 73% ORR in relapsed/refractory EMZL [20] , resulting in the wide use of this antibody as part of first-line treatment of MZLs [21] . Bortezomib has been associated with a 48% ORR in 32 patients with relapsed/refractory EMZL, but 71% of patients had early treatment discontinuation, often due to neurotoxicity or disease progression [22] . Everolimus has shown modest activity (ORR = 25%) in 20 patients with relapsed/refractory EMZL, with relevant side-effects that often resulted in dose reduction and/or early discontinuation [23] . To date, thalidomide and lenalidomide have been tested in small series of relapsed/refractory EMZL, with no responses among eight patients treated with thalidomide [24] , and three responses in seven patients treated with lenalidomide [25] . Although these comparisons should be done with caution, activity of HD-K seems to be similar, if not higher, to those reported with the other drugs, with the advantages of lower costs and better tolerability.
New strategies to further enhance clarithromycin activity deserve to be investigated. In particular, combinations with cytostatics and/or immunomodulators should be tested in The analysis of activity and efficacy according to primarily involved organ (ocular adnexae versus stomach versus lung) was not carried out because some subgroups were <5 cases. a Response to the previous therapeutic line (refractory = no response; relapsed = relapsing disease after initial response).
ORR, overall response rate; PFS, progression-free survival. original articles Annals of Oncology lymphoma patients. In line with in vitro and in vivo studies [6, 7] , a recent randomized trial demonstrated a synergistic effect of clarithromycin and conventional chemotherapy (CVP regimen: cyclophosphamide, vincristine, prednisone) in 60 patients with newly diagnosed indolent lymphomas [26] . The addition of clarithromycin has been associated with a significantly improvement in ORR and PFS, which has been related to a reduction of VEGF serum levels, suggesting an antiangiogenic effect of this macrolide [26] . As demonstrated for patients with multiple myeloma or Waldenström's macroglobulinemia [9, 10] , the combination of clarithromycin with lenalidomide could lead to an improved outcome without an excess in toxicity. A recent trial demonstrated that the addition of clarithromycin is able to revert the resistance to lenalidomide in myeloma patients [27] . All together, these findings suggest that a combination of clarithromycin and lenalidomide deserves to be assessed also in EMZL patients.
In conclusion, oral HD-K is safe and active in patients with relapsed/refractory EMZL. These results provide a satisfactory rationale for future investigations on the antiproliferative activity of clarithromycin, both alone and in combination with cytostatics and/or immunomodulators, in patients with EMZL and other lymphoma categories. Ancillary pharmacodynamic studies addressing the mechanisms by which clarithromycin is able to inhibit lymphoma growth may lead to an enhanced use of this antibiotic in multidrug combinations.
